← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-03-28 15:00:00 | Takeda’s Zasocitinib Delivered Rapid And Durable Skin Clearance In A Convenient Once-daily Pill, Affirming Promise To Reshape Psoriasis Care Osaka, japan & cambridge, mass.--(business wire)--takeda’s zasocitinib delivered rapid and durable skin clearance in a convenient once-daily pill, affirming promise to reshape psoriasis care. |
| 2026-03-02 02:00:00 | Takeda And Protagonist Announce U.s. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Rusfertide As A Potential First-in-class Therapy For Polycythemia Vera Osaka, japan & cambridge, mass. & newark, calif.--(business wire)--takeda (tse:4502/nyse:tak) and protagonist therapeutics, inc. (“protagonist”) (nasdaq:ptgx) today announced that the u.s. food and drug administration (fda) accepted the new drug application (nda) and granted priority review for rusfertide. rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (pv). the fda has set a prescription drug user fee act. |
| 2026-02-19 12:00:00 | Positive Phase 3 Data Demonstrate Potential For Entyvio® (vedolizumab) To Address Treatment Gap For Children And Adolescents With Moderate To Severe Ulcerative Colitis Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive data from the pivotal phase 3 kepler trial, which demonstrated that entyvio® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (uc), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 the results, presented at the 21st c. |
| 2026-02-10 03:15:00 | U.s. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takeda’s Oveporexton (tak-861) As A Potential First-in-class Therapy For Narcolepsy Type 1 Osaka, japan & cambridge, mass.--(business wire)--fda accepts new drug application and grants priority review for takeda’s oveporexton as a potential first-in-class therapy for narcolepsy type 1. |
| 2026-02-09 08:00:00 | Iambic Announces Collaboration With Takeda To Advance Ai-driven Design Of Small Molecules San diego & cambridge, mass.--(business wire)--iambic, a clinical-stage life science and technology company developing novel medicines using its ai-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with takeda that will use iambic’s industry leading ai drug discovery models to advance a select set of high-priority small molecule programs, initially in takeda’s oncology and gastrointestinal and inflammation therapeutic areas. |
| 2026-01-29 01:37:00 |
|
| 2026-01-05 07:00:00 |
|
| 2025-12-18 03:00:00 |
|
| 2025-12-06 09:30:00 |
|
| 2025-11-19 06:30:00 |
|
| 2025-11-07 11:00:00 |
|
| 2025-10-30 03:04:00 |
|
| 2025-10-21 20:25:00 |
|
| 2025-10-14 05:00:00 |
|
| 2025-09-23 18:04:00 |
|
📰 Browse additional press releases for Takeda Pharmaceutical!
Sign up for free or log in⚡ Instantly access "The Checklist Value Investor — A Smarter Way to Pick Stocks" — free!